Research
Moderna's RSV vaccine shown to provide strong protection against serious cases in adults 50 and older
The Brief
- A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented RSV infections.
- The vaccine was 60.2% protective against RSV-associated emergency department or urgent care encounters.
- The vaccine was 81.8% protective against RSV-associated hospitalizations in the study population, which the source reports as adults 50 and older.
Why it matters
The results add efficacy data for an RSV vaccine in older adults, a group at higher risk of serious RSV disease, which can inform vaccination decisions and public health planning.
Who’s affected
- adults 50 and older
- clinicians and public health planners
- #rsv
- #vaccines
- #mrna
- #respiratory infections
- #public health
A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented respiratory syncytial virus (RSV) infections, 60.2% against RSV-associated emergency department or urgent care encounters and 81.8% against RSV-associated hospitalizations in a population of…